SCHEMBL2276392

SCHEMBL2276392

O=C(Nc1cc(Oc2ccccc2)ccc1C(=O)O)c1ccc(N2CCCCC2)nc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.50
CYP3A4 P08684 1/20 0.47
SOAT1 P35610 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC2 Q92769 1/20 0.47
KCNH2 Q12809 1/20 0.47
CSF1R P07333 1/20 0.47
DAPK1 P53355 1/20 0.47
SERPINE1 P05121 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
HDAC1 Q13547 1/20 0.45
EGLN1 Q9GZT9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272304 0.90 NPC1 (0.55) DGAT1KCNH2CSF1RDAPK1
SCHEMBL2275080 0.88 HDAC1 (0.46) DGAT1CYP3A4SOAT1HDAC3HDAC2
SCHEMBL2278079 0.86 HDAC2 (0.63) HDAC3HDAC2KCNH2TRPV1HDAC1
SCHEMBL2270356 0.86 SERPINE1 (0.48) DGAT1SERPINE1
SCHEMBL2274078 0.83 SMN1; SMN2 (0.49) HDAC3HDAC2KCNH2TRPV1HDAC1
SCHEMBL2271588 0.78 SERPINE1 (0.64) SERPINE1
SCHEMBL1316626 0.77 SIRT6 (0.45) CSF1RSERPINE1
SCHEMBL27696834 0.77 MCHR1 (0.60) TRPV1HDAC1
SCHEMBL2273868 0.76 NPC1 (0.57) HDAC3HDAC2SERPINE1HDAC1
SCHEMBL2272389 0.76 NTRK1 (0.64) HDAC3HDAC2SERPINE1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 DGAT1 3774/4885CYP3A4 1614/4885SOAT1 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.